Expert Interview
Evaluating Eli Lilly's Retatrutide's (once-weekly triple hormone receptor agonist) Phase 3 Clinical Data for Obesity Management
Ticker(s): LLY, NVO, REGN, PFE, VKTXInstitution: University of Arkansas Medical Center
- Director of the diabetes program at UAMS Health
- Manages about 600 patients with type 2 diabetes/obesity and 200 patients on insulin pumps
- Clinical and research interests include type 1 diabetes, type 2 diabetes, Diabetes management with exercise, insulin pumps, closed-look insulin pump systems, and continuous glucose monitoring systems
How many patients do you manage that have obesity?
Added By: allan_adminOn a scale(1-10) how excited are you for Eli Lilly's triple agonist, Retatrutide ?
Added By: allan_adminWhat are the pros/cons of a triple agonist in weight loss treatment?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
